Galera Therapeutics (Galera Therapeutics) Short Interest

View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Galera Therapeutics's Short Interest

For the Biotechnology subindustry, Galera Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Short Interest falls into.

Galera Therapeutics (Galera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 134, Malvern, PA, USA, 19355

Website

https://www.galeratx.com

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.

Executives

Mark Bachleda	officer: Chief Commercial Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen	director, officer: President and CEO	7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy	officer: Chief Medical Officer	2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey	officer: See Remarks	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund	officer: Chief Medical Officer
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman	officer: Chief Accounting Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p.	10 percent owner	C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025